Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification (AACR 2013)

HMPL-504_PreclinicalWithIressa_AACR_2013-page-0